默沙东与卫材宣布,Welireg® (Belzutifan)联合Lenvima® (Lenvatinib)在某些既往治疗的晚期肾细胞癌患者中已达成无进展生存期 (PFS) 的主要终点。
默沙东与卫材宣布,Welireg® (Belzutifan)联合Lenvima® (Lenvatinib)在某些既往治疗的晚期肾细胞癌患者中已达成无进展生存期 (PFS) 的主要终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.